Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas

Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas

Dades bibliogràfiques
Autors principals:	Wordsworth, P, Dijkmans, B, van der Heijde, D, Davis, J, Schiff, M, Kivitz, A, Sieper, J, Mease, P, Kupper, H, Wong, R, Grp, A
Format:	Conference item
Publicat:	2008

Ítems similars

CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL
per: Wordsworth, P, et al.
Publicat: (2009)

Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS.
per: van der Heijde, D, et al.
Publicat: (2006)

Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS)
per: van der Heijde, D, et al.
Publicat: (2008)

Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial.
per: Van der Heijde, D, et al.
Publicat: (2005)

Adalimumab enhances health-related quality of life in patients with active ankylosing spondylitis - Results from the atlas trial
per: van der Heijde, D, et al.
Publicat: (2006)

Adalimumab improves physical functioning and work productivity in ankylosing spondylitis (AS) patients: Results from ATLAS.
per: van der Heijde, D, et al.
Publicat: (2006)

Adalimumab Reduces Pain, Fatigue, and Stiffness in Patients with AS: Results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for AS (ATLAS) (vol 35, pg 1346, 2008)
per: Revicki, D, et al.
Publicat: (2011)

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
per: Revicki, D, et al.
Publicat: (2008)

Improved physical functioning and work productivity in ankylosing spondylitis (AS) patients who were treated with adalimumab-ATLAS trial results
per: Vanderheijde, D, et al.
Publicat: (2007)

Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS
per: Désirée van der Heijde, et al.
Publicat: (2019-11-01)

Improvements in health related quality of life (HRQL) correlate positively with clinical reponses in ankylosing spondylitis (AS) patients - Results from ATLAS
per: Van der Heijde, D, et al.
Publicat: (2006)

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
per: Rudwaleit, M, et al.
Publicat: (2009)

Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging
per: Baraliakos, X, et al.
Publicat: (2011)

Efficacy and safety of adalimumab (Humira (R)) in European clinical practice: The ReAct trial
per: Burmester, G, et al.
Publicat: (2005)

Adalimumab is effective and well-tolerated in patients with ankylosing spondylitis (AS) in day-to-day clinical practice - Results from rhapsody
per: Wordsworth, P, et al.
Publicat: (2008)

Efficacy and safety of adalimumab in the treatment of Rheumatoid Arthritis (RA) in real-life clinical practice: 1-year-results of the react study
per: Burmester, G, et al.
Publicat: (2006)

IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS), ADALIMUMAB IMPROVES INFLAMMATORY BOWEL DISEASE (IBD) AND PSORIASIS (Ps) AND PREVENTS ANTERIOR UVEITIS (AU) FLARES
per: Wordsworth, P, et al.
Publicat: (2009)

Predictors of good clinical response (BASDAI 50 or ASAS partial remission) in 1,250 patients treated with adalimumab (humira (R)) for active ankylosing spondylitis (AS)
per: Rudwaleit, M, et al.
Publicat: (2008)

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial
per: Désirée van der Heijde, et al.
Publicat: (2018-03-01)

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
per: Choy, E, et al.
Publicat: (2007)

Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira (R)) treatment
per: Burmester, G, et al.
Publicat: (2007)

Adalimumab (HUMIRA (R)) improves inflammatory bowel disease (IBD) and psoriasis (Ps) and prevents anterior uveitis (AU) flares in patients with Ankylosing spondylitis (AS)
per: Rudwaleit, M, et al.
Publicat: (2008)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
per: Yijia Jiang, et al.
Publicat: (2023-08-01)

Baricitinib versus placebo or adalimumab in rheumatoid arthritis
per: Taylor, P, et al.
Publicat: (2017)

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
per: Amies Karen, et al.
Publicat: (2011-10-01)

EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS
per: Van Laar, J, et al.
Publicat: (2012)

Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study
per: Maxime Dougados, et al.
Publicat: (2020-01-01)

Efficacy of adalimumab in sarcoidosis
per: van Hagen P M, et al.
Publicat: (2010-11-01)

First expirience of adalimumab administration in Russia: preliminary results of an open 24 week study
per: E L Luchichina, et al.
Publicat: (2008-10-01)

The efficacy of adalimumab on experimentally induced spinal cord ischemia-reperfusion injury
per: Yasar Karatas, et al.
Publicat: (2020-06-01)

Adalimumab
per: Nilgun Atakan
Publicat: (2022-04-01)

A104
per: V. Rybko, et al.
Publicat: (2015-11-01)

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
per: Kavanaugh, A, et al.
Publicat: (2005)

Atlas of spinal operations /
per: Bauer, R. 544660, et al.
Publicat: (1993)

Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis
per: Baraliakos, X, et al.
Publicat: (2013)

Efficacy and safety of monotherapy with sirukumab compared to adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study
per: Taylor, P, et al.
Publicat: (2018)

Adalimumab for the treatment of psoriasis
per: D Turner, et al.
Publicat: (2009-09-01)

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study
per: Robert Landewé, et al.
Publicat: (2019-06-01)

Safety of treatment with adalimumab
per: G. V. Lukina, et al.
Publicat: (2008-04-01)

LONG TERM INHIBITION OF IL-17A WITH SECUKINUMAB REDUCES SPINAL INFLAMMATION BUT HAS NO INFLUENCE ON FATTY LESIONS AS ASSESSED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS
per: Baraliakos, X, et al.
Publicat: (2013)